Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Vivani Medical Presents Development Plans for Once- or Twice-Yearly Semaglutide Implant

By Public Technologies
  • Vivani Medical expects top-line results from its SLIM-1 Phase 1 trial of semaglutide implant NPM-139 in November 2026.
  • All SLIM-1 patients were successfully dosed in August 2026; a Phase 2 dose-ranging study is projected to start in 2027.
  • NPM-139 targets once- or twice-yearly dosing for chronic weight management in obese or overweight patients.
  • Novo Nordisk's evaluation of NPM-139 remains ongoing.
  • Cash runway is expected to fund the current operating plan, including key milestones, into mid-2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivani Medical Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.